Key Events This Week
09 Feb: Q3 FY26 results reveal revenue decline and margin erosion
10 Feb: Downgrade to Strong Sell amid weak fundamentals and bearish technicals
13 Feb: Stock closes at Rs.14.31, down 3.83% on the day
Mar 05
BSE+NSE Vol: 3.25 k

Tejnaksh Healthcare Ltd’s shares touched a fresh 52-week low of Rs.12.1 today, marking a significant milestone in the stock’s ongoing decline. The healthcare services company has seen its share price fall sharply over the past year, reflecting persistent challenges in its financial performance and market positioning.
Read full news article
09 Feb: Q3 FY26 results reveal revenue decline and margin erosion
10 Feb: Downgrade to Strong Sell amid weak fundamentals and bearish technicals
13 Feb: Stock closes at Rs.14.31, down 3.83% on the day

Tejnaksh Healthcare Ltd has seen its investment rating downgraded from Sell to Strong Sell as of 9 February 2026, reflecting deteriorating technical indicators and persistent fundamental weaknesses. Despite a very attractive valuation, the company’s flat financial performance, declining profitability, and bearish technical trends have prompted a reassessment of its outlook within the Healthcare Services sector.
Read full news articleTejnaksh Healthcare Ltd's latest financial results indicate significant challenges in its operational performance. For the quarter ended December 2025, the company reported consolidated net sales of ₹2.62 crores, reflecting a year-on-year decline of 17.87%. This marks the third consecutive quarter of revenue contraction, with previous quarters also showing declines of 15.38% and 11.57%. The persistent decrease in sales suggests underlying structural issues rather than temporary fluctuations. The company's consolidated net profit for the same period was ₹0.30 crores, which represents a substantial year-on-year decline of 50.82%. This decline in profitability is accompanied by a decrease in the profit after tax margin, which fell to 11.07% from 17.55% in the previous year. The operating margin also experienced compression, dropping to 26.34%, down from 35.42% in the prior year, indicating significant operati...
Read full news article
Tejnaksh Healthcare Ltd., a Mumbai-based speciality urology hospital operator, reported a consolidated net profit of ₹0.30 crores for Q3 FY26, marking a sharp 50.82% decline year-on-year from ₹0.61 crores in Q3 FY25. The micro-cap company, with a market capitalisation of ₹32.00 crores, witnessed its third consecutive quarter of revenue contraction, raising concerns about operational sustainability in an otherwise resilient healthcare services sector.
Read full news articleTejnaksh Healthcare Ltd's latest financial results for the quarter ended September 2025 reveal significant operational challenges. The company reported a decline in net sales by 11.57% year-on-year, amounting to ₹2.98 crores, marking the second consecutive quarter of negative year-on-year growth. While there was a sequential improvement of 12.88% from the previous quarter, the overall revenue remains below levels achieved in comparable quarters of the prior fiscal year. The consolidated net profit for the same quarter was ₹0.31 crores, reflecting a substantial year-on-year decline of 50.00%. This decline is indicative of the pressures faced by the company, as the operating profit margin contracted sharply to 26.17%, down 820 basis points from the previous year. The margin compression suggests that rising operational costs or pricing pressures have not been adequately offset by volume growth or efficiency g...
Read full news article
Tejnaksh Healthcare Ltd has seen its investment rating upgraded from Strong Sell to Sell, driven primarily by a shift in technical indicators despite ongoing challenges in financial performance and valuation metrics. The company’s technical trend has improved from bearish to mildly bearish, prompting a reassessment of its market stance. However, fundamental weaknesses and valuation concerns continue to weigh on investor sentiment.
Read full news article
Tejnaksh Healthcare Ltd’s shares declined sharply to a fresh 52-week low of Rs.12.55 on 27 Jan 2026, marking a significant milestone in the stock’s downward trajectory amid broader market weakness and company-specific performance concerns.
Read full news article
Tejnaksh Healthcare Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 2 January 2026, driven primarily by a shift in technical indicators despite persistent fundamental challenges. The healthcare services company’s Mojo Score improved to 31.0, reflecting a nuanced market view that balances technical recovery against ongoing financial underperformance and valuation considerations.
Read full news articlePlease refer standalone and consolidated unaudited result for the quarter ended 31st December 2025.
In continuation of our Letter dated 2th February 2026 we wish to inform you that a meeting of the Board of Directors of the Company was held on Saturday 7th February 2026 at Shop No 1 Building Name: Shivprasad Harihar Singh Compound Block Sector: Jogeshwari East Road: Caves Road. Pratap Nagar -Mumbai Maharashtra 400060 to at 4.00 pm. and has transacted the following: - 1. Considered and approved Un-Audited Financial Results (Standalone & Consolidated) for the quarter ended on 31th December 2025 and took note of Limited Review Report thereon in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015; The meeting of Board of Directors commenced at 4:00 pm and concluded at 6.00 pm This is for your information and record.
Respected Sir/Madam Please refer letter attached for your reference. Thanks Afrin Shaikh
No Upcoming Board Meetings
No Dividend history available
Tejnaksh Healthcare Ltd has announced 5:10 stock split, ex-date: 19 Jul 23
Tejnaksh Healthcare Ltd has announced 36:10 bonus issue, ex-date: 26 Apr 18
No Rights history available